Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.45 -3.3%	$1.59	$0.99 ▼ $6.14	$137.20M	2.74	1.34 million shs	1.23 million shs
CRDF Cardiff Oncology	$2.10 +1.0%	$3.12	$2.06 ▼ $5.64	$138.37M	1.54	1.52 million shs	862,176 shs
FBRX Forte Biosciences	$11.00 -2.0%	$11.22	$4.11 ▼ $28.68	$139.62M	2.91	73,170 shs	177,688 shs
MDCX Medicus Pharma	$1.94 -3.0%	$2.62	$1.80 ▼ $8.94	$35.63M	N/A	401,684 shs	310,578 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	-3.33%	-10.49%	-7.05%	-22.46%	-74.74%
CRDF Cardiff Oncology	+0.96%	-9.48%	-15.66%	-37.13%	-8.30%
FBRX Forte Biosciences	-2.05%	-3.76%	+7.95%	+30.95%	+3,457.57%
MDCX Medicus Pharma	-3.00%	-12.61%	-22.40%	-20.82%	+193,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.4757 of 5 stars	3.5	4.0	1.6	0.8	0.6
CRDF Cardiff Oncology	2.0933 of 5 stars	3.4	1.0	2.7	1.7	0.6
FBRX Forte Biosciences	2.5744 of 5 stars	3.5	3.0	2.1	1.7	0.6
MDCX Medicus Pharma	1.6779 of 5 stars	3.8	0.0	1.9	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$14.43	895.07% Upside
CRDF Cardiff Oncology	2.83	Moderate Buy	$10.10	380.95% Upside
FBRX Forte Biosciences	3.00	Buy	$68.00	518.18% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	1,111.34% Upside

Current Analyst Ratings Breakdown

Latest MDCX, CRDF, FBRX, and CABA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/18/2025	FBRX Forte Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/18/2025	FBRX Forte Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$75.00
8/15/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
8/13/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
8/6/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $10.00
7/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
7/8/2025	CRDF Cardiff Oncology	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$19.00
7/1/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/24/2025	CRDF Cardiff Oncology	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$3.50
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00

(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.95 per share	N/A
CRDF Cardiff Oncology	$680K	205.46	N/A	N/A	$0.88 per share	2.39
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$7.93 per share	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$115.86M	-$2.71	N/A	N/A	N/A	N/A	-92.11%	-74.08%	11/13/2025 (Estimated)
CRDF Cardiff Oncology	-$45.43M	-$0.87	N/A	N/A	N/A	-9,344.14%	-77.94%	-63.65%	11/6/2025 (Estimated)
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-85.38%	-72.34%	11/13/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.34	N/A	N/A	N/A	N/A	-549.30%	-228.06%	N/A

Latest MDCX, CRDF, FBRX, and CABA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FBRX Forte Biosciences	-$1.21	-$0.96	+$0.25	-$0.96	N/A	N/A
8/11/2025	Q2 2025	MDCX Medicus Pharma	-$0.39	-$0.43	-$0.04	-$0.43	N/A	N/A
8/7/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	-$0.73	-$0.02	-$0.73	$4.17 million	N/A
7/29/2025	Q2 2025	CRDF Cardiff Oncology	-$0.19	-$0.21	-$0.02	-$0.21	$0.11 million	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	4.78	4.78
CRDF Cardiff Oncology	N/A	4.42	4.42
FBRX Forte Biosciences	N/A	11.74	11.74
MDCX Medicus Pharma	N/A	1.29	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
CRDF Cardiff Oncology	16.29%
FBRX Forte Biosciences	77.63%
MDCX Medicus Pharma	N/A

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
CRDF Cardiff Oncology	7.70%
FBRX Forte Biosciences	5.90%
MDCX Medicus Pharma	11.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	91.46 million	81.18 million	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
FBRX Forte Biosciences	5	12.43 million	11.70 million	Optionable
MDCX Medicus Pharma	N/A	17.82 million	15.82 million	N/A

MDCX, CRDF, FBRX, and CABA Headlines

Recent News About These Companies

Medicus Pharma nears FDA milestone in cancer trial - ICYMI

August 30 at 12:28 PM | proactiveinvestors.com

Medicus Pharma's (MDCX) "Buy" Rating Reiterated at D. Boral Capital

August 25, 2025 | americanbankingnews.com

Medicus Pharma Completes Equity Sales to Yorkville

August 22, 2025 | msn.com

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of ...

August 21, 2025 | finance.yahoo.com

Medicus Pharma Advances D-MNA Clinical Program and Expands Strategic Partnerships

August 21, 2025 | tipranks.com

Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights

August 21, 2025 | newsfilecorp.comN

Biotech at a Pivotal Moment: Four Stocks Defining The Transformation (MDCX, IOBT, INSM, RNA)

August 20, 2025 | theglobeandmail.com

Biotech’s Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA)

August 19, 2025 | theglobeandmail.com

Q3 EPS Forecast for Medicus Pharma Decreased by Analyst

August 19, 2025 | americanbankingnews.com

Medicus Pharma Ltd to Acquire Antev Ltd in Strategic Expansion Move

August 7, 2025 | theglobeandmail.com

Medicus Pharma Seeks FDA Fast-Track Approval for Innovative Skin Cancer Treatment

August 7, 2025 | theglobeandmail.com

Medicus Pharma announces MoU with HelixNano

August 4, 2025 | thepharmaletter.comT

Medicus Pharma and HelixNano agree outline deal to develop heat-stable vaccines

August 4, 2025 | proactiveinvestors.com

Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines

August 4, 2025 | newsfilecorp.comN

Medicus Pharma Appoints Deloitte for Licensing Deal

July 30, 2025 | tipranks.com

Medicus Pharma Ltd. Strengthens Board with New Appointments

July 23, 2025 | tipranks.com

Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders

July 23, 2025 | newsfilecorp.comN

Medicus Pharma Ltd. Announces Submission of Type C Meeting Request to ...

July 23, 2025 | finanznachrichten.de

Medicus Pharma Ltd.: Medicus Pharma Ltd Announces a Definitive ...

July 23, 2025 | finanznachrichten.de

Medicus Pharma Ltd. Expands Clinical Trials and Announces Strategic Acquisition

July 21, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDCX, CRDF, FBRX, and CABA Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.45 -0.05 (-3.33%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.48 +0.03 (+2.34%)

As of 08/29/2025 07:56 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Cardiff Oncology NASDAQ:CRDF

$2.10 +0.02 (+0.96%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$2.12 +0.02 (+0.71%)

As of 08/29/2025 07:52 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Forte Biosciences NASDAQ:FBRX

$11.00 -0.23 (-2.05%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$11.01 +0.01 (+0.08%)

As of 08/29/2025 04:15 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Medicus Pharma NASDAQ:MDCX

$1.94 -0.06 (-3.00%)

As of 08/29/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time